Small molecule · Inhibitor of hypoxia-inducible factor prolyl hydroxylase (EGLN1) · developed by Kyntra Bio
Roxadustat is an orally bioavailable hypoxia-inducible factor prolyl hydroxylase inhibitor. It blocks degradation of HIF transcription factors, increasing endogenous erythropoietin production, reducing hepcidin and improving iron availability. It is studied in anemia, myelodysplastic syndrome and anemia in chronic kidney disease patients on dialysis.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04059913 | Phase 4 | CKD Anemia in Dialysis Participants | Completed | KYNB |
| NCT03303066 | Phase 2/3 | Anemia | Completed | KYNB |
| NCT02952040 | Phase 1 | Healthy Subjects | Completed | KYNB |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
AnemiaCKD Anemia in Dialysis ParticipantsHealthy SubjectsMyelodysplastic Syndrome
Updated Oct 18, 2026. Something wrong or missing? Report it on the KYNB page.
See KYNB's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
KYNB catalysts and pipeline →